loading
前日終値:
$46.84
開ける:
$46.92
24時間の取引高:
47.28M
Relative Volume:
3.34
時価総額:
$101.69B
収益:
$47.64B
当期純損益:
$5.42B
株価収益率:
17.55
EPS:
2.67
ネットキャッシュフロー:
$13.09B
1週間 パフォーマンス:
-5.81%
1か月 パフォーマンス:
-2.11%
6か月 パフォーマンス:
-18.26%
1年 パフォーマンス:
+14.18%
1日の値動き範囲:
Value
$46.72
$47.40
1週間の範囲:
Value
$46.39
$49.44
52週間の値動き範囲:
Value
$39.35
$63.33

Bristol Myers Squibb Co Stock (BMY) Company Profile

Name
名前
Bristol Myers Squibb Co
Name
セクター
Healthcare (1174)
Name
電話
(609) 252-4621
Name
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
職員
34,100
Name
Twitter
@BMSNEWS
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
BMY's Discussions on Twitter

BMY を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
46.86 101.69B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.73 724.64B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
149.79 376.43B 89.33B 21.81B 18.57B 8.99
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
73.77 352.49B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.30 334.73B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
115.77 234.21B 53.22B 12.86B 14.85B 6.39

Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-04-22 開始されました Cantor Fitzgerald Neutral
2025-04-22 開始されました Piper Sandler Overweight
2024-12-16 アップグレード Jefferies Hold → Buy
2024-12-10 再開されました BofA Securities Neutral
2024-11-15 開始されました Wolfe Research Peer Perform
2024-11-13 アップグレード Daiwa Securities Neutral → Outperform
2024-11-12 アップグレード Leerink Partners Market Perform → Outperform
2024-10-25 ダウングレード Citigroup Buy → Neutral
2024-10-17 開始されました Bernstein Mkt Perform
2024-07-29 ダウングレード Barclays Overweight → Equal Weight
2024-03-11 ダウングレード Societe Generale Buy → Hold
2024-02-06 ダウングレード Redburn Atlantic Buy → Neutral
2024-01-03 ダウングレード BofA Securities Buy → Neutral
2023-11-15 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-11-09 開始されました Deutsche Bank Hold
2023-11-02 ダウングレード Daiwa Securities Outperform → Neutral
2023-10-27 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-10-27 アップグレード HSBC Securities Reduce → Hold
2023-10-27 ダウングレード William Blair Outperform → Mkt Perform
2023-10-20 再開されました UBS Neutral
2023-07-14 開始されました HSBC Securities Reduce
2023-07-10 開始されました SVB Securities Market Perform
2023-06-28 開始されました Daiwa Securities Outperform
2023-03-06 開始されました Jefferies Hold
2023-01-17 開始されました Cantor Fitzgerald Overweight
2022-11-18 開始されました Credit Suisse Neutral
2022-10-10 ダウングレード Guggenheim Buy → Neutral
2022-09-14 ダウングレード Berenberg Buy → Hold
2022-06-03 ダウングレード Raymond James Outperform → Mkt Perform
2022-04-06 再開されました Morgan Stanley Underweight
2021-12-17 開始されました Goldman Buy
2021-12-09 再開されました Wells Fargo Equal Weight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-11-01 ダウングレード Argus Buy → Hold
2021-07-27 再開されました Truist Buy
2021-04-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2021-04-13 アップグレード Truist Hold → Buy
2020-11-16 アップグレード Societe Generale Hold → Buy
2020-11-10 再開されました Bernstein Mkt Perform
2020-11-06 ダウングレード Gabelli & Co Buy → Hold
2020-10-19 アップグレード Guggenheim Neutral → Buy
2020-09-29 開始されました Berenberg Buy
2020-07-28 開始されました Raymond James Outperform
2020-04-02 アップグレード Morgan Stanley Equal-Weight → Overweight
2020-03-23 ダウングレード Societe Generale Buy → Hold
2020-02-27 開始されました Barclays Equal Weight
2020-01-06 再開されました Citigroup Buy
2019-12-13 アップグレード Argus Hold → Buy
2019-11-22 再開されました Morgan Stanley Equal-Weight
2019-10-17 再開されました BofA/Merrill Buy
2019-08-14 アップグレード Atlantic Equities Neutral → Overweight
2019-05-28 開始されました Goldman Buy
2019-05-20 ダウングレード Argus Buy → Hold
2019-05-03 アップグレード Barclays Equal Weight → Overweight
2019-05-03 再開されました JP Morgan Overweight
2019-01-15 アップグレード Societe Generale Sell → Buy
2018-10-22 ダウングレード Citigroup Buy → Neutral
すべてを表示

Bristol Myers Squibb Co (BMY) 最新ニュース

pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Collaborates on Alzheimer's Drug Deve - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol-Myers (NYSE:BMY) Squibb Dividend Update Reflects Steady Healthcare NYSE Composite - Kalkine Media

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol-Myers Squibb (NYSE:BMY) Declares US$0.62 Common and US$0.50 Preferred Dividends - Yahoo

Jun 18, 2025
pulisher
Jun 18, 2025

BioNTech and Bristol Myers Squibb Collaborate on BNT327, a PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb to present positive new data on lymphoma treatment - Pharmafile

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BMY Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb declares quarterly dividend of $0.62 per share By Investing.com - Investing.com Nigeria

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb Announces Dividend - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol-Myers Expands in Cancer Care With $1.35B OncoACP3 Deal - Insider Monkey

Jun 17, 2025
pulisher
Jun 17, 2025

Editas Medicine Is Great. Here's Why You Shouldn't Buy It. - The Motley Fool

Jun 17, 2025
pulisher
Jun 17, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Therapy - geneonline.com

Jun 17, 2025
pulisher
Jun 17, 2025

Bristol Myers Squibb Presents Promising Blood Cancer Drug Data at EHA Congress - MSN

Jun 17, 2025
pulisher
Jun 16, 2025

Bristol Myers Squibb (BMY) Shares Cross 5% Yield Mark - Nasdaq

Jun 16, 2025
pulisher
Jun 16, 2025

Myocardial Infarction Market Is Booming So Rapidly 2025-2032 - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Vanguard Health Care Fund's Strategic Moves: A Closer Look at Bristol-Myers Squibb Co - Yahoo Finance

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol-Myers Squibb (BMY) Announces Positive Data From the Pivotal Phase 3 POETYK PsA-1 Trial - MSN

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers Squibb (BMY) Achieves Strong Results with Breyanzi in Lymphoma Study - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers: positive phase 2 data in lymphoma - MarketScreener

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol Myers (BMY) Reports Promising Results from Lymphoma Stud - GuruFocus

Jun 16, 2025
pulisher
Jun 16, 2025

Schizophrenia Drugs Market Size, Share & Forecast 2025 | Major - openPR.com

Jun 16, 2025
pulisher
Jun 16, 2025

Bristol-Myers Squibb (BMY) Stock Analysis: Healthcare Giant with a 14.77% Potential Upside - DirectorsTalk Interviews

Jun 16, 2025
pulisher
Jun 16, 2025

Business development leadership team - Bristol Myers Squibb

Jun 16, 2025
pulisher
Jun 16, 2025

BioNTech and Bristol Myers Squibb Partner to Develop PD-L1xVEGF-A Bispecific Antibody for Cancer Treatment - geneonline.com

Jun 16, 2025
pulisher
Jun 16, 2025

Rockland Trust Co. Sells 20,035 Shares of Bristol-Myers Squibb (NYSE:BMY) - MarketBeat

Jun 16, 2025
pulisher
Jun 15, 2025

Jim Cramer on Bristol Myers: “We Need to See That Stock Back Up at $60” - Insider Monkey

Jun 15, 2025
pulisher
Jun 14, 2025

BioNTech and Bristol Myers Squibb Partner to Develop Bispecific Antibody Targeting PD-L1 and VEGF-A for Tumor Treatment - geneonline.com

Jun 14, 2025
pulisher
Jun 14, 2025

Bristol-Myers Squibb’s SWOT analysis: stock outlook amid Cobenfy growth and pipeline potential - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button' - Endpoints News

Jun 13, 2025
pulisher
Jun 12, 2025

Bristol Myers (BMY) Showcases Promising New Data on Targeted Pro - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers Promotes Attorney To Lead Corporate Affairs - Law360

Jun 12, 2025
pulisher
Jun 12, 2025

BioNTech and Bristol Myers Squibb Partner to Develop BNT327 Antibody Targeting PD-L1 and VEGF-A Pathways in Tumors - geneonline.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu Compared with Placebo in Adults with Psoriatic Arthritis - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating By Investing.com - Investing.com South Africa

Jun 12, 2025
pulisher
Jun 12, 2025

BMY Reports Positive Data on Sotyktu From Arthritis Study - TradingView

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb promotes Wendy Bartie to lead corporate affairs - PR Week UK

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers: new data to be presented in hematology - marketscreener.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol-Myers stock holds steady as Cantor maintains neutral rating - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA By Investing.com - Investing.com India

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb presents protein degradation data at EHA - Investing.com

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb Sets Q2 2025 Earnings Date: Key Financial Results Coming July 31 - Stock Titan

Jun 12, 2025
pulisher
Jun 12, 2025

Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - The Joplin Globe

Jun 12, 2025
pulisher
Jun 11, 2025

Bristol Myers Squibb (BMY) Exceeds Market Returns: Some Facts to Consider - MSN

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol-Myers Squibb (NYSE:BMY) Reports Positive Phase 3 Trial Results For Sotyktu - Yahoo Finance

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers at Goldman Sachs Conference: Strategic Insights on Growth - Investing.com Australia

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers bolsters radiopharma portfolio with PhiloChem deal - BioPharma Dive

Jun 11, 2025
pulisher
Jun 11, 2025

Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol Myers (BMY) Sees Promising Results for Sotyktu in Phase 3 Trial - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

BioNTech and Bristol Myers Squibb Collaborate on PD-L1xVEGF-A Bispecific Antibody for Tumor Treatment - geneonline.com

Jun 11, 2025
pulisher
Jun 11, 2025

Bristol-Myers Squibb To Present At Goldman Sachs Global Conference; Webcast At 10:00 AM ET - Nasdaq

Jun 11, 2025

Bristol Myers Squibb Co (BMY) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Bristol Myers Squibb Co (BMY) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Hickey Benjamin
President, RayzeBio Org.
May 09 '25
Sale
38.01
97
3,702
0
Hirawat Samit
EVP,Chief Med.Offr.,Drug Dev.
Apr 25 '25
Buy
47.58
4,250
202,215
83,513
Shanahan Karin
EVP, Glob. Prod. Dev. & Supply
Apr 01 '25
Option Exercise
0.00
3,306
0
15,489
Plenge Robert M
EVP, Chief Research Officer
Mar 10 '25
Option Exercise
0.00
11,255
0
20,148
Meyers Gregory Scott
EVP, Chief Digital & Tech Off.
Mar 10 '25
Option Exercise
0.00
23,150
0
26,937
Shanahan Karin
EVP, Glob. Prod. Dev. & Supply
Mar 10 '25
Option Exercise
0.00
20,423
0
22,339
Lenkowsky Adam
EVP, Chief Commercial Officer
Mar 10 '25
Option Exercise
0.00
16,684
0
20,017
Poole Ahn Amanda
EVP, Chief People Officer
Mar 10 '25
Option Exercise
0.00
7,164
0
8,546
LEUNG SANDRA
EVP, General Counsel
Mar 10 '25
Option Exercise
0.00
48,718
0
386,496
Hoch Lynelle
President, Cell Therapy Org.
Mar 10 '25
Option Exercise
0.00
7,446
0
7,920
drug_manufacturers_general SNY
$47.86
price up icon 0.50%
$108.50
price up icon 0.46%
drug_manufacturers_general PFE
$23.97
price up icon 0.38%
$289.33
price down icon 0.10%
drug_manufacturers_general MRK
$79.06
price down icon 0.29%
drug_manufacturers_general NVS
$115.77
price down icon 0.16%
大文字化:     |  ボリューム (24 時間):